One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Arcellx stock cleared that benchmark Friday, with a jump from 79 to 83 Friday.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Is Arcellx Stock A Buy?
Arcellx stock has climbed more than 5% past a 48.91 entry in a third-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The biotech stock reported 0% EPS growth in its most recent report, while sales growth came in at 119%.
Arcellx stock earns the No. 38 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group.
